|

Retatrutide Clinical Trials

3 actively recruiting trials across 2 locations

No change since May 2026

Also known as: LY3437943

Pipeline

Phase 1: 1Phase 3: 2

Top Sponsors

  • Eli Lilly and Company3

Indications

  • Diabetes2
  • Liver Disease1
  • Insulin Sensitivity1
  • Metabolic Dysfunction-Associated Steatotic Liver Disease1
  • Diabetes Mellitus1

Other1 trial

A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Phase 1

Tuscaloosa, Alabama1 trial

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

MFA Clinical Research

Phase 3

Phoenix, Arizona1 trial

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Arizona Research Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.